Thursday, March 8, 2012

Insurance companies sues innovators for discounting Copays

Innovators have been curbing generic penetration by way of discounting copays to generic levels. The practice not only impacts the profits of insurers, but also drives up healthcare costs of the nation.   Pfizer Recently discounted Lipitor copays to generic levels in an attempt to make sure that consumers stick to the brand name, despite availability of cheaper generics . This practice has been grown very rapidly in the past few years

The companies that have been sued are Abbott Laboratories, Amgen Inc., AstraZeneca P.L.C., Bristol-Myers Squibb Co., GlaxoSmithKline P.L.C., Merck & Co., Novartis AG, and Pfizer Inc.